(Q34851726)

4 August 2017

1 reference

title

Atypical antipsychotics in Parkinson-sensitive populations (English)

1 reference

4 August 2017

1 reference

2

Hubert H Fernandez

1 reference

4 August 2017

1

Joseph H Friedman

1 reference

4 August 2017

publication date

1 January 2002

1 reference

Journal of Geriatric Psychiatry and Neurology

4 August 2017

published in

1 reference

4 August 2017

volume

15

1 reference

4 August 2017

issue

3

1 reference

4 August 2017

page(s)

156-170

1 reference

Visual hallucinations associated with Parkinson disease.

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Psychosis and Other Psychiatric Manifestations of Levodopa Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Metabolic modification of Parkinson's disease and of chronic manganese poisoning

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Psychiatric Side Effects of Levodopa in Man

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Mental symptoms in Parkinsonian patients treated with L-dopa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Psychiatric symptoms in Parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Risk factors for nursing home placement in advanced Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Levodopa-induced psychosis: a kindling phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Clozapine: a 2-year open trial in Parkinson's disease patients with psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Clozapine prevents recurrence of psychosis in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Clozapine treatment of parkinsonism with psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Clozapine for psychosis in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Clozapine treatment of psychosis in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Clozapine for the treatment of levodopa-induced psychosis in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Clozapine use in Parkinson's disease: a retrospective analysis of a large multicentered clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Clozapine for the treatment of psychosis in Parkinson's disease: chart review of 49 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Clozapine. A novel antipsychotic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

The emerging role of clozapine in the treatment of movement disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Treatment of parkinsonian tremor with clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Clozapine-responsive tremor in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Benztropine versus clozapine for the treatment of tremor in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Clozapine in Parkinson's disease tremor. Effects of acute and chronic administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Clozapine-induced agranulocytosis. Incidence and risk factors in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Nocturnal akathisia in Parkinson's disease: treatment with clozapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Suppression of dyskinesias in advanced Parkinson's disease: moderate daily clozapine doses provide long-term dyskinesia reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Suppression of dyskinesias in advanced Parkinson's disease. II. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Risperidone for hallucinations in levodopa-treated Parkinson's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: an open-label, long-term study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Risperidone treatment of drug-related psychosis in patients with parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Worsening of motor features of parkinsonism with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: a cautionary note

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Olanzapine for psychosis in patients with Parkinson's disease with and without dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Efficacy and safety of clozapine and olanzapine: an open-label study comparing two groups of Parkinson's disease patients with dopaminergic-induced psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Deterioration of parkinsonian symptoms following treatment of dopaminergic hallucinosis with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Quetiapine (Seroquel) in the treatment of psychosis in patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Efficacy of quetiapine in Parkinson's patients with psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Quetiapine for l-dopa-induced psychosis in PD

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Quetiapine for l-dopa-induced psychosis in PD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Extrapyramidal signs and other neurologic findings in clinically diagnosed Alzheimer's disease. A community-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Extrapyramidal signs in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Pathological correlates of extrapyramidal signs in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Parkinsonism in patients with vascular dementia: clinical, computed- and positron emission-tomographic findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Gait initiation by patients with lower-half parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Clozapine in the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Clozapine in Older Patients With Psychosis and Behavioral Disruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Efficacy of risperidone for behavioral disorders in the elderly: a clinical observation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Risperidone treatment of behavioral disturbances in outpatients with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

The use of risperidone in severely demented patients with persistent vocalizations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Risperidone: treatment response in adult and geriatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Long-Term use of quetiapine in elderly patients with psychotic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Neuroleptic sensitivity to risperidone in Lewy body dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Mechanisms of action of atypical antipsychotic drugs: a critical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Underrecognition of tardive dyskinesia and drug-induced parkinsonism by psychiatric residents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Drug-induced parkinsonism in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Prevalence, clinical characteristics, and pharmacologic treatment of Parkinson's disease in residents in long-term care facilities. SAGE Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Experience with the Atypical Antipsychotics - Risperidone and Olanzapine in the Elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Quetiapine as an Alternative to Clozapine in the Treatment of Dopamimetic Psychosis in Patients with Parkinson's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

Efficacy and Tolerability of Olanzapine in Elderly Patients with Psychotic Disorders: A Prospective Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F089198870201500307

10.1177/089198870201500307

21 January 2018

Identifiers

DOI

1 reference

4 August 2017

1 reference